Spots Global Cancer Trial Database for metastatic renal cell cancer
Every month we try and update this database with for metastatic renal cell cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | NCT02579811 | Metastatic Rena... | Axitinib | 18 Years - | Case Comprehensive Cancer Center | |
| Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma | NCT02689167 | Kidney Neoplasm... Metastatic Rena... | Sunitinib | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma | NCT02555748 | Metastatic Rena... | Pazopanib Sunitinib | 18 Years - | Institut Claudius Regaud | |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | NCT00923845 | Renal Cell Carc... Graft-Versus-Ho... Engraftment Syn... | Pentostatin Sirolimus Cyclophosphamid... Allogeneic Hema... Th2 rapa cells Donor Lymphocyt... Induction Thera... GVHD prophylaxi... Donor Hematopoi... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | NCT02579811 | Metastatic Rena... | Axitinib | 18 Years - | Case Comprehensive Cancer Center | |
| Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer | NCT02843607 | Metastatic Rena... | Cryosurgery NK immunotherap... | 30 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | NCT00027820 | Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child... | Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M... | - | Fred Hutchinson Cancer Center | |
| Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib | NCT01246843 | Metastatic Rena... GIST | 18 Years - | Radboud University Medical Center | ||
| Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | NCT01100242 | Metastatic Rena... | Velcade and Sor... | 18 Years - | New Mexico Cancer Care Alliance | |
| Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer | NCT00446368 | Carcinoma, Rena... | RAD001 | 18 Years - | The Methodist Hospital Research Institute | |
| Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 | NCT01884961 | Metastatic Rena... Malignant Melan... | Boost of radiot... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer | NCT00091611 | Kidney Neoplasm... | IL-2 (interleuk... OKT3 Cyclophosphamid... Fludarabine Mesna | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | NCT00670748 | Metastatic Mela... Metastatic Rena... Metastatic Canc... | Anti-NY ESO-1 T... aldesleukin Cyclophosphamid... fludarabine pho... ALVAC NY ESO-1 ... | 18 Years - 66 Years | National Institutes of Health Clinical Center (CC) | |
| Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | NCT05263609 | Renal Cell Canc... | Axitinib Pembrolizumab | 18 Years - 99 Years | University of Oklahoma | |
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | NCT00393029 | Anti-p53 TCR-Ge... | anti-protein 53... aldesleukin filgrastim cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer | NCT02899078 | Metastatic Rena... Stage IV Renal ... | Ibrutinib Nivolumab | 18 Years - | University of California, Davis | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT01767636 | Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Pazopanib Hydro... | 18 Years - | Mayo Clinic | |
| Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer | NCT02664883 | Healthy Subject Metastatic Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal... | Computed Tomogr... Cytology Specim... Laboratory Biom... Magnetic Resona... | 25 Years - | University of Southern California | |
| Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib | NCT01246843 | Metastatic Rena... GIST | 18 Years - | Radboud University Medical Center | ||
| Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | NCT03092856 | Clear Cell Rena... Metastatic Rena... Recurrent Renal... Stage IV Renal ... | Anti-OX40 Antib... Axitinib Laboratory Biom... Placebo | 18 Years - | University of Southern California | |
| Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | NCT02626130 | Clear Cell Rena... Metastatic Rena... Stage IV Renal ... | Cryosurgery Laboratory Biom... Therapeutic Con... Tremelimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer | NCT02626130 | Clear Cell Rena... Metastatic Rena... Stage IV Renal ... | Cryosurgery Laboratory Biom... Therapeutic Con... Tremelimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | NCT03229278 | Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So... | Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab | 18 Years - | Rutgers, The State University of New Jersey | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT01767636 | Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Pazopanib Hydro... | 18 Years - | Mayo Clinic | |
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | NCT00393029 | Anti-p53 TCR-Ge... | anti-protein 53... aldesleukin filgrastim cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | NCT01100242 | Metastatic Rena... | Velcade and Sor... | 18 Years - | New Mexico Cancer Care Alliance | |
| Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma | NCT00903175 | Renal Cell Carc... | everolimus sunitinib | 18 Years - | Novartis | |
| Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer | NCT02664883 | Healthy Subject Metastatic Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal... | Computed Tomogr... Cytology Specim... Laboratory Biom... Magnetic Resona... | 25 Years - | University of Southern California | |
| Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | NCT00393029 | Anti-p53 TCR-Ge... | anti-protein 53... aldesleukin filgrastim cyclophosphamid... fludarabine pho... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | NCT02318771 | Head and Neck S... Metastatic Rena... Recurrent Head ... Recurrent Lung ... Recurrent Renal... Recurrent Skin ... Stage III Renal... Stage IV Lung C... Stage IV Skin M... | Radiation Thera... MK-3475 | 18 Years - | Thomas Jefferson University | |
| Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma | NCT00903175 | Renal Cell Carc... | everolimus sunitinib | 18 Years - | Novartis | |
| Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 | NCT01884961 | Metastatic Rena... Malignant Melan... | Boost of radiot... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
